63results about How to "Increase insulin levels" patented technology

Derivatives of glucagon-like peptide I (GLP-1) and especially GLP-1 (7-37) have been found to have insulinotropic activity. The invention pertains to a composition comprising an acid addition salt of GLP-I (7-37) and to a composition comprising a carboxylate salt of GLP-I (7-37). The invention also pertains to method of treating type II diabetes mellitus by providing derivatives of GLP-I (7-37) to the patient.

A method of glucose level control comprising providing at least one electrode adapted to apply an electric field to a pancreas; and applying an electric field to the pancreas using said at least one electrode such that blood glucose levels are significantly reduced and blood insulin levels are not significantly increased compared to a regular insulin response in a same person.

A method of glucose level control comprising, providing at least one electrode adapted to apply an electric field to a pancreas; and applying an electric field to the pancreas using said at least one electrode such that blood glucose levels are significantly reduced and blood insulin levels are not significantly increased compared to a regular insulin response in a same person.

A method of glucose level control, comprising providing at least one electrode adapted to apply an electric field to a pancreas; and applying an electric field to the pancreas using the above-mentioned at least one electrode such that blood glucose levels are significantly reduced and blood insulin levels are not significantly increased.

A method of infusing liquid medicaments including insulin via an insulin pump, includes identifying an insulin delivery protocol associated with ingestion of carbohydrates wherein the insulin delivery protocol is likely to lead to a postprandial drop in blood glucose to a level below a basal level, then proposing at least one alternative insulin delivery protocol to inhibit the postprandial drop in blood glucose by delivering a metered amount of insulin that is appropriate to facilitate the metabolism of the carbohydrates without the postprandial blood glucose level drop. The invention further includes querying the patient as to whether to apply the alternative insulin delivery protocol, receiving instructions from the patient in response to the query, and applying the alternative insulin delivery protocol following receiving instructions from the patient to apply the alternative insulin delivery protocol.

The subject invention provides compositions and methods for treating diabetes in patients. In a preferred embodiment, the invention provides compositions methods for treating diabetes and / or preventing or alleviating complications associated with diabetes. Specifically exemplified herein is the concurrent administration of a cysteamine compound with at least one additional therapeutic agent to prevent and / or treat diabetes as well as prevent and / or treat complications associated with diabetes. In a preferred embodiment, oral administration of cysteamine hydrochloride with Metformin to a patient diagnosed with diabetes can substantially regulate the patient's glucose metabolism and insulin sensitivity.

The subject invention provides compositions and methods for treating diabetes in patients. In a preferred embodiment, the invention provides compositions methods for treating diabetes and / or preventing or alleviating complications associated with diabetes. Specifically exemplified herein is the concurrent administration of a cysteamine compound with at least one additional therapeutic agent to prevent and / or treat diabetes as well as prevent and / or treat complications associated with diabetes. In a preferred embodiment, oral administration of cysteamine hydrochloride with Metformin to a patient diagnosed with diabetes can substantially regulate the patient's glucose metabolism and insulin sensitivity.

The present invention provides pharmaceutical compositions comprising at least one polypeptide having GLP-1 activity wherein an effective dose of said pharmaceutical composition comprises 15 mg, 30 mg, 50 mg or 100 mg of said polypeptide having GLP-1 activity. Also provided are methods of administering the pharmaceutical compositions of the invention.

A composition of bio-active compounds and methods for facilitating and supporting the metabolism and transport of glucose and carbohydrates into muscle cells. Preferably, the composition of bio-active compounds include 4-hydroxyisoleucine and one or more amino acids selected from the group consisting of arginine, aspartate, threonine, serine, glutamate, proline, glycine, alanine, cysteine, valine, methionine, isoleucine, leucine, tryptophan, phenylalanine, ornithine, lysine, histidine, gamma-amino butyrate, and trimethylhistidine. In one presently preferred embodiment of the present invention, the bio-active compounds are extracted from fenugreek seeds. A method for extracting a composition of bio-active compounds from fenugreek seeds is also disclosed, wherein the method comprises the steps of: (1) providing a plurality of fenugreek seeds; (2) preparing the fenugreek seeds; and (3) extracting a composition of bio-active compounds from the fenugreek seeds, wherein the bio-active compounds comprise 4-hydroxyisoleucine and one or more amino acids selected from the group consisting of arginine, aspartate, threonine, serine, glutamate, proline, glycine, alanine, cysteine, valine, methionine, isoleucine, leucine, tryptophan, phenylalanine, ornithine, lysine, histidine, gamma-amino butyrate, and trimethylhistidine. The composition of bio-active compounds and methods for extraction of same preferably include between about 10% and 70% of 4-hydroxyisoleucine and between about 20% and 40% of the amino acids.

A method of infusing liquid medicaments including insulin via an insulin pump, includes identifying an insulin delivery protocol associated with ingestion of carbohydrates wherein the insulin delivery protocol is likely to lead to a postprandial drop in blood glucose to a level below a basal level, then proposing at least one alternative insulin delivery protocol to inhibit the postprandial drop in blood glucose by delivering a metered amount of insulin that is appropriate to facilitate the metabolism of the carbohydrates without the postprandial blood glucose level drop. The invention further includes querying the patient as to whether to apply the alternative insulin delivery protocol, receiving instructions from the patient in response to the query, and applying the alternative insulin delivery protocol following receiving instructions from the patient to apply the alternative insulin delivery protocol.

The present invention generally provides therapeutic compositions and methods for treating a disease, disorder, or injury characterized by a deficiency in the number or biological activity of a cell of interest. The method provides compositions for generating reprogrammed cells or for increasing regeneration in a cell, tissue, or organ of interest. Such methods are useful for treating subjects having a deficiency in a particular cell type or in a polypeptide produced by that cell type. In particular, the invention provides prophylactic and therapeutic methods and compositions for ameliorating or preventing hyperglycemia associated with type I and type II diabetes and related complications.

α2-Heremans Schmid Glycoprotein (AHSG) inhibits insulin-induced autophosphorylation of the insulin receptor (IR) and IR-tyroskine kinase (TK) activity; genetic ablation of the Ahsg gene enhances insulin signal transduction and increase whole-body insulin sensitivity. Therefor, AHSG and its gene(s) are useful targets for agents that inhibit the development or progression of Type II diabetes or any disease or disorder associated with increased insulin resistance. Provided herein is a method for inhibiting the biological activity of AHSG protein in a cell using compounds that inhibit phosphorylation of AHSG. Also disclosed is a method of augmenting the phosphorylation or IR-TK activity in a liver or muscle cell by providing a compound that lowers the amount of active AHSG or inhibits the biological activity of AHSG. Such effects may be achieved by delivering an antisense nucleic acid construct that hybridizes with AHSG encoding DNA. This invention includes a method (a) treating a subject that is susceptible to, or suffers from, obesity and insulin resistance or (b) increasing insulin sensitivity, and thereby preventing or treating insulin resistance in the subject. The method comprises lowering the amount of active AHSG or inhibiting the biological activity of AHSG in the subject, preferably in liver or muscle, by using AHSG antisense constructs or an anti-AHSG antibody. In a subject eating a high fat diet, the effect on body weight gain and / or insulin resistance is diminished, and total body fat content is lowered, by lowering the amount of active AHSG or inhibiting the action of the AHSG in the subject using the agents noted above.

A method whereby the blood pressure metabolism in an individual showing evidence of dysregulation is improved when that person receives an appropriate oral administration of (−)-hydroxycitric acid. The potassium salt of (−)-hydroxycitric acid is a preferred form of the compound, followed by the sodium salt, then by the amide and other derivatives of the acid. The regulation of blood pressure levels over any given period of time may be improved with a controlled release form of (−)-hydroxycitric acid. Controlled release can be used to provide a sustained and modulated amount of the active to the body as desired and therefore regulate the use of the compound as a hypotensive agent.

The present invention provides a health-care medicine composition and its preparation method. Said method includes the following steps: making photosynthetic bacterial pool, Chinese herbal medicine liquor, mineral solution and honey undergo the process of biological fermentation, then making them be combined with lactic acid microbial pool, yeast microbial pool, Cram-positive actinomycetes bacterial pool and filamentous microbial pool of fermentation line to form five family microbial community to obtain mother culture, then making said mother culture and nucleic acid, vitamin, SOD and amino acid undergo the process of biological emulsification so as to obtain the invented composition. Said composition has extensive application in preparation of medicine for curing broad-spectrum bacterial disease, broad-spectrum viral disease, damaged gene and diseases due to damaged cell, and specially for preventing and curing SARS.

The invention relates to a hypoglycemic traditional Chinese medicine composition and a preparation method thereof. The traditional Chinese medicine composition comprises 18 drug substances, namely rhizoma anemarrhenae, cortex phellodendri, trichosanthes root, prepared rehmannia root, figwort root, asparagus, milk vetch, cortex lycii radicis, adenophora stricta, dendrobe, fragrant solomonseal rhizome, shizandra berry, radix codonopsitis, fructus ligustri lucidi, boxthorn fruit, yam, endothelium corneum gigeriae galli and kudzuvine root, and can be made into capsules, tablets, pills and granules with the addition of commonly used auxiliary materials in pharmaceutics; the preparation method of the composition has the characteristics of simplicity, practicability, scientificity and energy conservation.

A balanced food product and related method for preparation of the same is provided for optimizing the metabolism of the body of the consumer. The balanced food product may include a first fruit component, a second fruit component, and a protein component, as well as a sweetener component, and an oil binding agent component. Each of the components contributes an amount of carbohydrates, protein, and fat so as to yield a particular predetermined ratio therebetween and selectively provide a predetermined glycemic load to the consumer.

The present invention is related to the use of an overground part of Hedychium coronarium Koenig in lowering blood glucose, increasing insulin levels and treating and / or preventing diabetes without overly reducing blood glucose in a subject; i.e., not reducing blood glucose in a fasting subject. The present invention also relates to an extract and composition of the overground part of Hedychium coronarium Koenig and its use in lowering blood glucose, increasing insulin levels and treating and / or preventing diabetes.

The present invention provides amide-protected creatine molecules and compositions, containing one or more bioactive forms of creatine in aqueous compositions, wherein bioactive forms of creatine do not appreciably degrade into creatinine. Also provided are various beneficial effects of administering aqueous compositions having at least one amide-protected creatine molecule.

The invention relates to a traditional Chinese medicine composition for treating diabetes, and a preparation method and a detection method thereof. The traditional Chinese medicine composition is prepared by rhizoma anemarrhenae, ginseng, cortex phellodendri, radix trichosanthis, unprocessed rehmannia root, radix scrophulariae and the like. The detection method of the traditional Chinese medicine composition comprises the steps of thin-layer identifications of cortex phellodendri, cortex lycii radicis, fructus lycii, fructus schizandrae, glossy privet fruit and root of kudzu vine; and determination of sarsasapogenin content in the traditional Chinese medicine composition. The traditional Chinese medicine composition provided by the invention has the characteristics of simple and practical process, safety and efficiency, significant pharmacology and drug efficacy and clinical effects.

Compositions and methods for promoting weight management are taught by the present invention. Preferably, the methods include the step of administering a composition of bio-active compounds further including 4-hydroxyisoleucine and one or more amino acids selected from the group consisting of arginine, aspartate, threonine, serine, glutamate, proline, glycine, alanine, cysteine, valine, methionine, isoleucine, leucine, tryptophan, phenylalanine, ornithine, lysine, histidine, and gamma-aminobutyrate. In one presently preferred embodiment of the present invention, the bio-active compounds are extracted from fenugreek seeds. The methods of the present invention preferably include a composition of bio-active compounds with between about 10% and 70% of 4-hydroxyisoleucine and between about 20% and 40% of the amino acids. In presently preferred embodiments of the present invention, methods may work independently of or synergistically with insulin to stimulate the activity of glucose transport receptors located in muscle. More particularly, methods of the present invention may stimulate the activity of glucose transport receptor type 4. In another presently preferred embodiment of the present invention, a method for weight management includes the steps of: (1) performing a weight management analysis on an individual experiencing nutritional and metabolic deficiencies which impact proper metabolism of glucose and carbohydrates; (2) extracting a composition of bio-active compounds from fenugreek; and (3) administering the composition of bio-active compounds from fenugreek in an amount effective to enhance muscle glucose transportation within the body of the individual.

The present invention relates to a plant extract for treating diabetes and a process for making same. The plant extract of the invention is prepared from an overground part of Hedychium coronarium Koenig, which has the efficacies of lowering blood glucose, increasing insulin levels, reducing insulin resistance and treating and / or preventing diabetes without overly reducing blood glucose in a subject, i.e., not reducing blood glucose in a fasting subject. Also provided herein is a method for treating diabetes in a subject in need thereof comprising administering an effective amount of the plant extract to the subject.

The invention discloses a pharmaceutical composition with hypoglycemic function and preparation method thereof. The invention is made from bitter melon, anemarrhena, Tuber of Dwarf Lilyturf, picolinic acid and propolis according to a certain weight proportion; and it can be made into any common oral taken preparation form. The Chinese traditional medicine composition in the invention achieves hypoglycemic function, and can be used to treat diabetes.

Fried dough twists assisting in reducing blood fat comprise components in percentage by weight as follows: 30%-47% of tartary buckwheat powder and / or oat powder, 2%-6% of corn, 2%-6% of mung bean sprouts, 2%-6% of bitter gourds, 2%-6% of pepper, 2%-6% of onions, 15%-26% of wine, 4%-20% of cooked powder and 11%-35% of leavening dough; a production method of the cooked powder is as follows: taking 10 parts of grain powder and 2-4 parts of vegetable oil, heating the vegetable oil to the temperature of 190-240 DEG C, stirring the grain powder in the same direction while adding the heated vegetable oil, and evenly stirring the mixture. The fried dough twists assisting in reducing the blood fat and the production method of the fried dough twists have the advantages as follows: 1, the fried dough twists with the tartary buckwheat powder and / or the oat powder used as a main raw material are provided, are nutritious and delicious and can assist in reducing the blood fat of hyperlipidemia patients; 2, the production method of the fried dough twists with the tartary buckwheat powder and / or the oat powder used as the main raw material is provided, nutrition of the fried dough twists produced with the method cannot be lost during production, and the fried dough twists are crisp and tasty.

The invention relates to a marinating material, a marinated beancurd sheet and a preparation method thereof, and belongs to the technical field of food processing. The marinating material comprises the following main components: tea leaves, xylooligosaccharide, edible salt, soy sauce, hericium erinaceus powder, bamboo shoot powder, a yeast extract, star anise, cinnamon, amomum tsaoko, clove, pepper, dried orange peel, myrcia, radix angelicae, licorice, ginger, amomum villosum, amomum cardamomum, netmeg and edible oil. The components achieve a synergistic effect; through addition of the marinating material during production of a marinated product, the effect of endowing the marinated product with a good mouth feel is achieved, and the health-care effects of inhibiting bacteria, helping digestion, promoting absorption, lowering blood pressure and blood fat and the like are achieved.

The invention discloses a preparation method of an aspergillus-cristatus-contained Tibetan tea product. The preparation method comprises an aspergillus-cristatus-contained Tibetan tea processing step and a tea product directional and comprehensive extraction step. According to the preparation method, fresh tea leaves are firstly subjected to processes such as primary processing, deep fermentation, specific fermentation, so that specific effective compositions in tea leaf contents are richer; then, a composition which plays a core role in reducing blood sugar in aspergillus-cristatus-contained Tibetan tea and contains theabrown, polysaccharides, amino acids, crude proteins, potassium and calcium is directionally and comprehensively extracted through directional compound extraction to form an the aspergillus-cristatus-contained Tibetan tea product; and meanwhile, substances such as caffeine and tea polyphenols contained in dark tea are removed, so that the aspergillus-cristatus-contained Tibetan tea product can achieve a stable and efficient blood sugar reducing effect.

The present invention relates to a plant extract for treating diabetes and a process for making same. The plant extract of the invention is prepared from an overground part of Hedychium coronarium Koenig, which has the efficacies of lowering blood glucose, increasing insulin levels, reducing insulin resistance and treating and / or preventing diabetes without overly reducing blood glucose in a subject, i.e., not reducing blood glucose in a fasting subject. Also provided herein is a method for treating diabetes in a subject in need thereof comprising administering an effective amount of the plant extract to the subject.

Frozen confections having a combination of ingredients that provide outstanding organoleptic properties while at the same time ensuring a low glycemic product for consumption. In one aspect, the invention provides a frozen confection that comprises a natural nutritive sweetener, wherein the sweetener comprises kiwi, at least one glycoside, and at least one carbohydrate. The subject frozen confection is particularly advantageous because it does not significantly stimulate lipoprotein lipase (LPL), the fat storing enzyme. Moreover, the subject frozen confections are pleasing in taste, mouth-feel, and other organoleptic qualities without the use of artificial sweeteners or sucrose or high glycemic sugar.

The present invention provides a method for improving pancreatic function in a subject in need thereof, the method comprising administering to the subject STRO-1+ cells and / or progeny cells thereof and / or soluble factors derived therefrom. The method of the invention is useful for treating and / or preventing and / or delaying the onset or progression of a disorder resulting from or associated with pancreatic dysfunction, e.g., resulting from abnormal endocrine or exocrine function of the pancreas.